Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Blood

Volumn 113, Issue 16, 2009, Pages 3673-3678

  Treon, Steven P ^a   Branagan, Andrew R ^a   Ioakimidis, Leukothea ^a   Soumerai, Jacob D ^a   Patterson, Christopher J ^a   Turnbull, Barry ^b   Wasi, Parveen ^c   Emmanouilides, Christos ^d   Frankel, Stanley R ^e   Lister, Andrew ^f   Morel, Pierre ^g   Matous, Jeffrey ^h   Gregory, Stephanie A ⁱ   Kimby, Eva ^j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Biobridges Inc   (United States)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^d UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g Centre Hospitalier de LENS   (France)

^h Rocky Mountain Cancer Center   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHLORAMBUCIL; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ERYTHROPOIETIN; FAMCICLOVIR; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYDROCORTISONE; PARACETAMOL; RITUXIMAB; STEROID; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; LYMPHOMA; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; PARANEOPLASTIC NEUROPATHY; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; WALDENSTROEM MACROGLOBULINEMIA; CHEMICALLY INDUCED DISORDER; DIET THERAPY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SECOND CANCER; SURVIVAL RATE; TIME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; NEUTROPENIA; PNEUMONIA; PROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 65549105193     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-177329     Document Type: Article

References (40)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30:110-115. (Pubitemid 36506291)
2. Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392. (Pubitemid 24273002)
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
4. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood. 2006;107:3442-3446.
5. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994;12:2694-2698. (Pubitemid 24379658)
6. Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol. 1998;103:690-695. (Pubitemid 28545303)
7. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol. 1999;63:35-41. (Pubitemid 29305615)
8. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia: Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol. 1997;99:358-363.
9. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med. 1993;95:49-52.
10. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol. 1999;17:546-553. (Pubitemid 29075241)
11. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98:41-48
12. Leblond V, Ben Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol. 1998;16:2060-2064.
13. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol. 1993;11:1553-1558. (Pubitemid 23228262)
14. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525-1527. (Pubitemid 30017067)
15. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324. (Pubitemid 30056420)
16. Treon SP, Agus DB, Link B, et al. CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenström's macroglobulinemia. J Immunother. 2001;24:272-279. (Pubitemid 32479719)
17. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45:2047-2055. (Pubitemid 39232853)
18. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327-2333.
19. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005;16:132-138. (Pubitemid 40124490)
20. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in downregulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7:709-723. (Pubitemid 32707998)
21. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant ot the cytotoxic activity of either drug alone. Br J Haematol. 2001;114:800-809. (Pubitemid 32953735)
22. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038-1043. (Pubitemid 34525569)
23. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low grade or follicular lymphoma. J Clin Oncol. 2005;23:694-704. (Pubitemid 46224168)
24. Schulz K, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115-3120. (Pubitemid 35217057)
25. Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44:477-481. (Pubitemid 36113892)
26. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
27. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49-53. (Pubitemid 40053062)
28. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström's macroglobulinemia. Ann Oncol. 2004;15:1481-1483. (Pubitemid 39409737)
29. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M "flare" after rituximab therapy in patients with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101:2593-2598.
30. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2006;6:380-383.
31. Attal M, Harousseau JL, Facon T, et al. Single vs double transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
32. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473. (Pubitemid 44264086)
33. Treon SP, Pilarski LM, Belch AR, et al. CD20 directed therapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25:72-81.
34. Kraut EH, Crowley JJ, Grever MR, et al. Phase II study of fludarabine phosphate in multiple myeloma: a Southwest Oncology Group study. Invest New Drugs. 1990;8:199-200. (Pubitemid 20184235)
35. Helman DL, Byrd JC, Ales NC, et al. Fludarabine-related pulmonary: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest. 2002;122:785-790.
36. Leleu X, Soumerai JD, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström's macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250-255.
37. LeBlond V, Tamburini J, Levy V, et al. Incidence of disease transformation and development of MDS/AML in 165 patients with Waldenstrom macroglobulinemia treated with fludarabine based regimen in three studies [abstract]. Blood. 2007;110:388a.
38. Dimopoulos MA, Gertz M, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenström's macroglobulinemia. J Clin Oncol. 2009;27:120-126.
39. Nichols GL, Savage DG. Timing of rituximab/fludarabine in Waldenström's macroglobulinemia may avert hyperviscosity. Blood. 2004;104:237b.
40. Tedeschi A, Miqeleiz AS, Ricci F, et al. Fludarabine, cyclophosphamide, and rituximab and effective regimen characterized by high incidence of delayed responses in Waldenström's macroglobulinemia. Haematologica. 2007;92:226.